Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
F5 encodes an essential cofactor of the blood coagulation cascade. Additionally we are shipping Coagulation Factor V Kits (50) and Coagulation Factor V Proteins (22) and many more products for this protein.
Showing 10 out of 112 products:
These findings reveal a novel biological function and mechanism of the protein C (show PROC Antibodies) pathway in which protein S and the aPC (show APC Antibodies)-cleaved form of fV are cofactors for anti-inflammatory cell signaling by aPC (show APC Antibodies) in the context of endotoxemia and infection
Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of alpha1-antitrypsin.
The FVL mutation does not influence coagulation activation, lung inflammation or survival in lethal influenza A.
It suggested that there could be a combination of GLA (show GLA Antibodies) deficiency and FVL or other thrombosis-related gene defect in patients with genetic severe early-onset thrombosis.
Data suggest that tissue factor (show F3 Antibodies) and factor V induction by LPS (show TLR4 Antibodies) may in part accelerate mesangioproliferative glomerulonephritis through activation of factor X and downstream proinflammatory and procoagulant mechanisms.
The source of the FVL leading to accelerated thrombosis appears to be circulating, non-platelet-derived plasma FVL.
FVL has the ability to improve the hemophilia A or B phenotype, but this effect is principally evident at the microcirculation level following a particular vascular injury.
observations demonstrate a synergistic interaction between alpha-galactosidase A (show GLA Antibodies) deficiency and Factor V Leiden toward tissue fibrin deposition; concomitant mutations in these genes may increase the penetrance of vascular thrombotic events in humans
Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers.
The FVL mutation has no effect on the development of secondary tumours of colon cancer in livers of mice.
Case Report: acquired FV inhibitor that developed in a patient after exposure to human thrombin (show F2 Antibodies) used as a hemostatic agent during an otorhinolaryngology surgical procedure.
In the current study Factor V Leiden, prothrombin (show F2 Antibodies) G20210A, and thrombospondin-1 (show THBS1 Antibodies) polymorphisms showed no association with severity of hepatic fibrosis.
Chromosomal abnormalities and abnormalities in the genes related to thrombophilia such as FVL, MTHFR (show MTHFR Antibodies) and PTm mutations may be considered as risk factors for RM [recurrent miscarriage]
Given the essential role of platelet-derived factor Va in clot (show TXNDC17 Antibodies) formation, understanding the cellular and molecular mechanisms that regulate how platelets acquire this molecule will be important for the treatment of excessive bleeding or clotting
the diagnosis of an 'unaffected' foetus was offered. The child was subsequently followed up after delivery and was found to be normal for factor V levels with a normal genotype
Data (including data from case-control, genetic association studies) suggest that Factor V mutation Leiden is associated with significant genetic predisposition for venous thromboembolism (not thrombophilia) in pregnancy. [META-ANALYSIS, REVIEW]
FVL mutation is a significant determinant of coronary artery disease risk.
Activated protein C (show PROC Antibodies) has anti-inflammatory effects on human dendritic cells.
Polymorphisms in factor V and antithrombin III (show SERPINC1 Antibodies) gene in recurrent pregnancy loss
presence of three novel variants in F5 gene in Chilean patients with activated protein C (show PROC Antibodies) resistance; further studies are required to investigate the real contribution of these novel mutations to the APC (show APC Antibodies) resistance phenotype
Data suggest factor Xa (FXa (show F10 Antibodies)) and factor Va (FVa) compete to bind FXa (show F10 Antibodies) on both PS model membranes and microparticles from activated platelets; this competition between dimerization/prothrombinase (show FGL2 Antibodies) complex formation appears to regulate blood coagulation.
This gene encodes an essential cofactor of the blood coagulation cascade. This factor circulates in plasma, and is converted to the active form by the release of the activation peptide by thrombin during coagulation. This generates a heavy chain and a light chain which are held together by calcium ions. The activated protein is a cofactor that participates with activated coagulation factor X to activate prothrombin to thrombin. Defects in this gene result in either an autosomal recessive hemorrhagic diathesis or an autosomal dominant form of thrombophilia, which is known as activated protein C resistance.
coagulation factor V
, activated protein C cofactor
, activated protein c cofactor
, coagulation factor V jinjiang A2 domain
, factor V Leiden
, proaccelerin, labile factor